Literature DB >> 10094084

Symptom patterns of premenstrual dysphoric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders-IV.

S Gehlert1, C H Chang, S Hartlage.   

Abstract

Premenstrual dysphoric disorder was included in an appendix of DSM-III-R (revised third edition of the Diagnostic and Statistical Manual of Mental Disorders) and DSM-IV to facilitate systematic research. Items contained in its set of research criteria were considered tentative. Only one previous study of premenstrual symptoms specifically addressed symptoms of premenstrual dysphoric disorder, and it did not use DSM-IV criteria. In the present study, prospectively measured symptoms of 99 women were analyzed using exploratory principal components analysis with orthogonal rotation on all 24 items derived from the 11 symptoms listed in DSM-IV. Variation was found across phases of cycle and groups, with five factors predominating: (1) anger/irritability, (2) depressed mood, (3) anxiety/tension, (4) decreased energy and interest with physical symptoms, and (5) eating problems.

Entities:  

Mesh:

Year:  1999        PMID: 10094084     DOI: 10.1089/jwh.1999.8.75

Source DB:  PubMed          Journal:  J Womens Health        ISSN: 1059-7115            Impact factor:   2.681


  3 in total

1.  Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability.

Authors:  Ethan H Beckley; Angela C Scibelli; Deborah A Finn
Journal:  Psychoneuroendocrinology       Date:  2010-12-15       Impact factor: 4.905

2.  Premenstrual dysphoric symptoms amongst Brazilian college students: factor structure and methodological appraisal.

Authors:  Chei-Tung Teng; Antônio Helio Guerra Vieira Filho; Rinaldo Artes; Clarice Gorenstein; Laura H Andrade; Yuan-Pang Wang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

3.  The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women.

Authors:  S Gehlert; I H Song; C-H Chang; S A Hartlage
Journal:  Psychol Med       Date:  2008-03-26       Impact factor: 7.723

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.